Biophytis - LIVE HEALTHIER LONGER Revenue and Competitors

Paris, France

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Biophytis - LIVE HEALTHIER LONGER's estimated annual revenue is currently $4.8M per year.(i)
  • Biophytis - LIVE HEALTHIER LONGER's estimated revenue per employee is $155,000

Employee Data

  • Biophytis - LIVE HEALTHIER LONGER has 31 Employees.(i)
  • Biophytis - LIVE HEALTHIER LONGER grew their employee count by 0% last year.

Biophytis - LIVE HEALTHIER LONGER's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.6M81-5%N/AN/A
#2
$19.5M126-2%N/AN/A
#3
$36.3M23422%N/AN/A
#4
$19.7M127-17%N/AN/A
#5
$14.3M920%$179.5MN/A
#6
$49.4M208-8%€201.1MN/A
#7
$44.5M287-3%N/AN/A
#8
$7.6M49N/AN/AN/A
#9
$6.4M41N/AN/AN/A
#10
$17.2M111-15%N/AN/A
Add Company

What Is Biophytis - LIVE HEALTHIER LONGER?

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. Specifically, the company is advancing two proprietary drug candidates into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory. The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and collaborates with scientists at the Institute of Myology, and the Vision Institute

keywords:N/A

N/A

Total Funding

31

Number of Employees

$4.8M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Biophytis - LIVE HEALTHIER LONGER News

2022-04-17 - COVID-19 Treatment: Investigational Drugs and Other ...

Results from the multicenter phase 3 LIVE-AIR trial (n = 520) found ... A phase 1 trial completed in healthy volunteer in support of a...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.6M31-9%N/A
#2
$3.6M31-47%N/A
#3
$3.5M31N/AN/A
#4
$3.6M31N/AN/A
#5
$3.6M31N/AN/A